283 related articles for article (PubMed ID: 33834524)
21. The role of topical calcineurin inhibitors in atopic dermatitis.
Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
[TBL] [Abstract][Full Text] [Related]
22. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis.
Reitamo S; Remitz A; Kyllönen H; Saarikko J
Am J Clin Dermatol; 2002; 3(6):381-8. PubMed ID: 12113647
[TBL] [Abstract][Full Text] [Related]
23. Spotlight on topical pimecrolimus in atopic dermatitis.
Wellington K; Jarvis B
Am J Clin Dermatol; 2002; 3(6):435-8. PubMed ID: 12113651
[TBL] [Abstract][Full Text] [Related]
24. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
25. Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis.
Fröschl B; Arts D; Leopold C
GMS Health Technol Assess; 2007 Sep; 3():Doc09. PubMed ID: 21289943
[TBL] [Abstract][Full Text] [Related]
26. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
Sunderkötter C; Weiss JM; Bextermöller R; Löffler H; Schneider D
J Dtsch Dermatol Ges; 2006 Apr; 4(4):301-6. PubMed ID: 16638059
[TBL] [Abstract][Full Text] [Related]
27. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis.
El-Batawy MM; Bosseila MA; Mashaly HM; Hafez VS
J Dermatol Sci; 2009 May; 54(2):76-87. PubMed ID: 19303745
[TBL] [Abstract][Full Text] [Related]
28. Spotlight on topical pimecrolimus in pediatric atopic dermatitis.
Yang LP; Curran MP
Am J Clin Dermatol; 2010; 11(4):295-8. PubMed ID: 20509720
[TBL] [Abstract][Full Text] [Related]
29. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.
Gollnick H; Kaufmann R; Stough D; Heikkila H; Andriano K; Grinienko A; Jimenez P;
Br J Dermatol; 2008 May; 158(5):1083-93. PubMed ID: 18341665
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Hultsch T; Kapp A; Spergel J
Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
[TBL] [Abstract][Full Text] [Related]
31. Pimecrolimus 1% cream for the treatment of atopic dermatitis.
Wolff K
Skin Therapy Lett; 2005 Oct; 10(8):1-6. PubMed ID: 16292456
[TBL] [Abstract][Full Text] [Related]
32. Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children and sensitive skin areas.
Luger T; Chu CY; Elgendy A; Ibrahim SBBK; Murashkin N; Ranjan S; Zhao Z
Eur J Dermatol; 2023 Oct; 33(5):474-486. PubMed ID: 38297923
[TBL] [Abstract][Full Text] [Related]
33. [Safety of topical tacrolimus and pimecrolimus in children with atopic dermatitis].
Rodríguez Orozco AR; Ruiz Reyes H; Marín Hernández D
Rev Alerg Mex; 2005; 52(4):171-6. PubMed ID: 16268186
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
35. Topical tacrolimus in adult atopic dermatitis: a consensus based on a 15-year experience.
Calzavara-Pinton P; Fabbrocini G; Girolomoni G; Matiucci A; Micali G; Musumeci ML; Patruno C; Pellacani G; Rossi MT; Castello M; Stingeni L
G Ital Dermatol Venereol; 2020 Feb; 155(1):8-13. PubMed ID: 31760730
[TBL] [Abstract][Full Text] [Related]
36. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation.
Garside R; Stein K; Castelnuovo E; Pitt M; Ashcroft D; Dimmock P; Payne L
Health Technol Assess; 2005 Jul; 9(29):iii, xi-xiii,1-230. PubMed ID: 16022804
[TBL] [Abstract][Full Text] [Related]
37. Pimecrolimus in dermatology: atopic dermatitis and beyond.
Gisondi P; Ellis CN; Girolomoni G
Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
[TBL] [Abstract][Full Text] [Related]
38. [Long term management of childhood atopic dermatitis with calcineurin inhibitors].
Thaçi D
Hautarzt; 2003 May; 54(5):418-23. PubMed ID: 12719861
[TBL] [Abstract][Full Text] [Related]
39. Pimecrolimus: a review.
Gupta AK; Chow M
J Eur Acad Dermatol Venereol; 2003 Sep; 17(5):493-503. PubMed ID: 12941081
[TBL] [Abstract][Full Text] [Related]
40. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis.
Jensen JM; Scherer A; Wanke C; Bräutigam M; Bongiovanni S; Letzkus M; Staedtler F; Kehren J; Zuehlsdorf M; Schwarz T; Weichenthal M; Fölster-Holst R; Proksch E
Allergy; 2012 Mar; 67(3):413-23. PubMed ID: 22142306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
